Clonidine, a medication primarily known for treating high blood pressure, was well tolerated in mechanically ventilated critically ill adults when administered at intravenous doses up to 1800 micrograms per day. A secondary analysis of a prospective pharmacokinetic study found no evidence of dose-limiting toxicity within this range, suggesting that higher doses of the drug may be safe for further evaluation in future efficacy trials. The study, published in the Journal of Anesthesia, Analgesia and Critical Care, addresses a significant gap in clinical knowledge regarding the safety of using clonidine as an adjunct sedative in intensive care units (ICUs).
The research team, led by Huub L. A. van den Oever and colleagues, analyzed data from 32 critically ill adults who were consecutively enrolled in a dose-escalation project. These patients were divided into four groups of eight, receiving continuous intravenous infusions of 0, 600, 1200, or 1800 micrograms of clonidine per day. The 0 microgram group served as a control, allowing researchers to distinguish between adverse events caused by the underlying critical illness and those potentially linked to the medication. The study was conducted in the mixed medical-surgical ICU of Deventer Hospital between January 2017 and April 2018.
Clonidine acts on central alpha-2 adrenoceptors in the brainstem to reduce sympathetic tone and enhance vagal activity, which lowers heart rate and blood pressure while also producing sedation. While this mechanism is beneficial for hypertension, it poses potential risks in ICU patients where bradycardia and hypotension are common complications. The study aimed to determine whether these cardiovascular effects become clinically significant at the higher plasma concentrations required for sedation, a use that remains off-label in most countries.
To assess safety, the researchers monitored patients for serious adverse events (SAEs) and a predefined set of 45 adverse events (AEs) over a nine-day observation period. This included a 48-hour follow-up after clonidine discontinuation to detect any rebound phenomena, such as tachycardia or hypertension, which are potential consequences of withdrawing alpha-2 agonists. Half of the patients in the clonidine groups also underwent a four-hour loading phase where the infusion rate was tripled, providing data on safety during periods of higher initial drug exposure.
The results indicated that the frequency of serious adverse events was independent of the clonidine dose. Ten SAEs were reported across all groups, with Bayesian contingency table analysis providing strong evidence for no difference in SAE rates between the dose groups. Specifically, seven of these events were judged unlikely to be related to clonidine, while three were possibly related. No serious adverse events occurred during the loading phase, and no dose-limiting toxicity was observed, meaning the infusions were never interrupted for safety concerns.
Regarding common cardiovascular side effects, the study found no dose-dependent relationship between clonidine administration and bradycardia or hypotension. While bradycardia, defined as a heart rate below 60 beats per minute, was reported as an adverse event in seven patients, the statistical analysis did not support a meaningful increase in frequency with higher doses. Severe bradycardia, defined as a heart rate below 50 beats per minute, was identified in only three patients, most of whom were concurrently using beta-blockers. This finding contrasts with some other studies that reported higher rates of severe bradycardia, potentially due to differences in patient populations or sedation protocols.
An unexpected finding was that pleural effusions were more frequent in the control group than in the clonidine groups, with a Bayes factor of 12.9 favoring this difference. However, the authors noted that in the absence of a plausible pharmacological mechanism for clonidine to prevent pleural effusions, this signal is most likely attributable to chance. The study also found no clinically meaningful rebound tachycardia or hypertension after drug discontinuation. Mild fluctuations in heart rate and blood pressure were observed but were transient and comparable across all dose groups, including the control group.
The study had several limitations that must be considered when interpreting the results. The sample size was small, with only 32 patients, which limits the statistical power to detect uncommon but potentially important adverse events. The single-center design and the exclusion of patients with severe cardiovascular instability may also limit the generalizability of the findings to broader ICU populations. Additionally, clonidine was used strictly as an adjunct to standard sedation rather than as a sole agent, which may affect the applicability of the findings to different clinical scenarios.
The authors emphasized that the absence of dose-response relationships in adverse events was not masked by compensatory hemodynamic management. Baseline characteristics, including the severity of illness as measured by the APACHE IV score, were well balanced across the four dose groups. There were no discernible differences in the consumption of concomitant medications such as noradrenaline, midazolam, or beta-blockers between the groups. This suggests that the lack of differences in adverse event rates across dose levels was not due to altered clinical management in the higher dose groups.
This study represents the first systematic dose-escalation evaluation of clonidine for sedation in mechanically ventilated, critically ill adults with detailed safety monitoring. The high density of data points and continuous invasive monitoring provided precise observations of acute hemodynamic responses and potential withdrawal phenomena. The use of predefined criteria for adverse events enhanced the internal validity of the findings, although the small sample size and exploratory nature of the analysis mean that the possibility of type II error should be considered.
The findings provide a foundation for future efficacy-oriented trials that will need to establish the clinical utility and optimal dosing of clonidine in ICU patients. While the highest tolerated dose is not necessarily the optimal dose, the study defines a range up to 1800 micrograms per day that appears suitable for prospective evaluation. Future studies should consider doses that result in pharmacologically relevant drug exposure to properly assess potential benefits, such as reduced delirium or decreased requirements for other sedatives.
In conclusion, clonidine was well tolerated at doses up to 1800 micrograms per day when used as an adjunct to standard sedation in this cohort of mechanically ventilated, critically ill adults. The study did not find evidence of dose-limiting toxicity or a clear increase in hemodynamic adverse events with higher doses. These results support the safety of exploring clonidine at these doses in future clinical trials aimed at evaluating its efficacy in improving outcomes for ICU patients.
Historically developed in the 1960s to treat hypertension, clonidine targets brainstem nuclei regulating sympathetic activity. When treating high blood pressure, target plasma concentrations around 1 microgram per liter are generally sufficient, commonly attained with oral doses ranging from 200 to 600 micrograms per day. However, achieving therapeutic sedation demands substantially higher systemic exposures. Pediatric studies in ventilated children suggested targeting 2 micrograms per liter, while volunteer investigations in healthy adults noted noticeable sedation at concentrations averaging 1.96 micrograms per liter. In daily critical care practice, intravenous dosing previously evolved without formal trial guidance, spanning from 240 to 2400 micrograms daily across Dutch ICUs and up to 3360 micrograms daily in broader medical literature.
To maintain consistent drug delivery in the Deventer Hospital trial, hospital pharmacists diluted commercial ampoules of clonidine hydrochloride using 0.9 percent sodium chloride. Syringes were compounded to exact concentrations of 12.5, 25.0, and 37.5 micrograms per milliliter for the 600, 1200, and 1800 microgram daily cohorts, respectively. Maintenance infusions ran continuously at 2 milliliters per hour through dedicated catheter lumens, while the accelerated four-hour loading infusions were administered at 6 milliliters per hour. Patients were required to have proxy consent and an anticipated ventilation duration of at least three days. At baseline, clinicians excluded candidates with neurotrauma, post-anoxic coma, pregnancy, hepatic cirrhosis, severe heart failure, advanced atrioventricular block, renal failure, or clonidine exposure within the preceding 96 hours.
Throughout the multi-day observation, clinicians performed standardized evaluations three times daily, incorporating the Richmond Agitation and Sedation Scale alongside the Confusion Assessment Method score for the ICU to track cognitive and sedative depth. Concurrently, medical teams recorded arterial pressures, heart rates, and hours spent receiving mechanical ventilation. Over the entire nine-day study period, investigators tracked 349 predefined adverse events across the cohort, yielding a median of 11 categories per participant. These tracked categories encompassed occurrences of hypercapnia with arterial carbon dioxide tension of at least 6.2 kilopascals, hypoxaemia marked by arterial oxygen tension at or below 9.0 kilopascals, mean arterial pressures at or below 65 millimeters of mercury, and heart rates exceeding 100 beats per minute.
Across the four experimental groups, patients experienced a median intensive care unit stay of 13 days, and mortality did not differ between treatment groups. Two study participants died during the initial protocol follow-up period as reported serious adverse events, and two additional participants died later in the hospital following the conclusion of monitoring. The researchers also noted that days spent receiving active sedation, overall mechanical ventilation duration, and daily requirements for morphine, propofol, or haloperidol showed no discernible differences across the dose tiers. Because clinical sedation depth was titrated at physician discretion rather than governed by a fixed algorithmic protocol, future prospective efficacy studies will be needed to verify whether these elevated doses can actively spare concurrent sedative exposure.
Subject of Research: Safety and tolerability of high-dose intravenous clonidine for sedation in mechanically ventilated critically ill adults
Article Title: Safety and tolerability study of clonidine for sedation in mechanically ventilated adult patients
Article References: van den Oever, H. L. A., Zeeman, M., Klaas, E., Nassikovker, P., Bles, C., de Meijer, A. R., Kruisdijk-Gerritsen, A., & Arbouw, M. E. (2026). Safety and tolerability study of clonidine for sedation in mechanically ventilated adult patients. Journal of Anesthesia, Analgesia and Critical Care, 6(1), Article 116. https://doi.org/10.1186/s44158-026-00447-y
Image Credits: AI Generated
DOI: 10.1186/s44158-026-00447-y
Keywords: clonidine, ICU sedation, mechanical ventilation, dose-escalation, pharmacokinetics, adverse events, bradycardia, hypotension, critical care, Bayesian analysis, rebound phenomena, adjunctive therapy, hemodynamic monitoring, alpha-2 agonist, clinical trial, pleural effusion, sedative safety, intensive care, drug tolerability, secondary analysis
News Source: Ophelia Keating. (November 20, 2026). High-dose clonidine safe for ventilated ICU patients. Scienmag.



